
CJC-1295 No DAC
10 mg
Modified GHRH (1–29) analog without albumin binding, used as a short-duration receptor reference.
Free U.S. shipping $175+

GHRP-2 is a synthetic hexapeptide developed as a growth hormone releasing peptide and characterized as an agonist at the growth hormone secretagogue receptor.
It appears throughout the secretagogue literature as a reference compound, and is frequently used in laboratory research to benchmark newer, more selective receptor agonists against an earlier, well-documented ligand.
For research use only — not for human or animal consumption.
Supplied solely for legitimate laboratory and research purposes. Not for medical or veterinary use, diagnosis, treatment, or prevention of disease.
Analytical values reflect per-lot documentation and appear once a batch is released.
Topics reflect published preclinical and in vitro research. Reference only — not a claim of clinical outcomes.
The GHRP family of hexapeptides was developed in the 1980s in the search for orally active growth hormone secretagogues.
GHRP-2 has been used in decades of published receptor pharmacology work and remains a reference compound in the field.

10 mg
Modified GHRH (1–29) analog without albumin binding, used as a short-duration receptor reference.

5/5 mg
Combined GHRH analog and secretagogue receptor agonist preparation for dual-input pituitary research.

5 mg
GHRH analog with Drug Affinity Complex modification for extended-duration receptor research.

10 mg
Early growth hormone releasing hexapeptide widely cited as a ghrelin receptor research standard.